TY - JOUR
T1 - Incidence and severity prediction score of COVID-19 in people living with HIV (SCOVHIV)
T2 - experience from the first and second waves of the pandemic in Indonesia
AU - Yunihastuti, Evy
AU - Karjadi, Teguh Harjono
AU - Widhani, Alvina
AU - Mahdi, Haridana Indah Setiawati
AU - Sundari, Salma
AU - Hapsari, Aljira Fitya
AU - Koesnoe, Sukamto
AU - Djauzi, Samsuridjal
N1 - Funding Information:
The authors would like to acknowledge the staff collecting data in the medical record of each hospital; Dede Bahtiar (Cipto Mangunkusumo Hospital), Dyaning Arie Saliring Tyas (Sentra Medika Hospital), Mustika Munthe Kristia (Dharmais National Cancer Hospital).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: People living with HIV (PLHIV) have higher risk of COVID-19 infection and mortality due to COVID-19. Health professionals should be able to assess PLHIV who are more likely to develop severe COVID-19 and provide appropriate medical treatment. This study aimed to assess clinical factors associated with COVID-19 severity and developed a scoring system to predict severe COVID-19 infection among PLHIV. Methods: This retrospective cohort study evaluated PLHIV at four hospitals diagnosed with COVID-19 during the first and second wave COVID-19 pandemic in Indonesia. The independent risk factors related to the severity of COVID-19 were identified with multivariate logistic regression. Results: 342 PLHIV were diagnosed with COVID-19, including 23 with severe-critical diseases. The cumulative incidence up to December 2021 was 0.083 (95% CI 0.074–0.092). Twenty-three patients developed severe-critical COVID-19, and the mortality rate was 3.2% (95% CI 1.61%–5.76%). Having any comorbidity, CD4 count of < 200 cells/mm3, not being on ART, and active opportunistic infection were independent risk factors for developing severe COVID-19. SCOVHIV score was formulated to predict severity, with 1 point for each item. A minimum score of 3 indicated a 58.4% probability of progressing to severe COVID-19. This scoring system had a good discrimination ability with the area under the curve (AUC) of 0.856 (95% CI 0.775–0.936). Conclusion: SCOVHIV score, a four-point scoring system, had good accuracy in predicting COVID-19 severity in PLHIV.
AB - Background: People living with HIV (PLHIV) have higher risk of COVID-19 infection and mortality due to COVID-19. Health professionals should be able to assess PLHIV who are more likely to develop severe COVID-19 and provide appropriate medical treatment. This study aimed to assess clinical factors associated with COVID-19 severity and developed a scoring system to predict severe COVID-19 infection among PLHIV. Methods: This retrospective cohort study evaluated PLHIV at four hospitals diagnosed with COVID-19 during the first and second wave COVID-19 pandemic in Indonesia. The independent risk factors related to the severity of COVID-19 were identified with multivariate logistic regression. Results: 342 PLHIV were diagnosed with COVID-19, including 23 with severe-critical diseases. The cumulative incidence up to December 2021 was 0.083 (95% CI 0.074–0.092). Twenty-three patients developed severe-critical COVID-19, and the mortality rate was 3.2% (95% CI 1.61%–5.76%). Having any comorbidity, CD4 count of < 200 cells/mm3, not being on ART, and active opportunistic infection were independent risk factors for developing severe COVID-19. SCOVHIV score was formulated to predict severity, with 1 point for each item. A minimum score of 3 indicated a 58.4% probability of progressing to severe COVID-19. This scoring system had a good discrimination ability with the area under the curve (AUC) of 0.856 (95% CI 0.775–0.936). Conclusion: SCOVHIV score, a four-point scoring system, had good accuracy in predicting COVID-19 severity in PLHIV.
KW - COVID-19
KW - HIV
KW - Incidence
KW - Indonesia
KW - Severity prediction score
UR - http://www.scopus.com/inward/record.url?scp=85139093928&partnerID=8YFLogxK
U2 - 10.1186/s12981-022-00472-1
DO - 10.1186/s12981-022-00472-1
M3 - Article
C2 - 36192742
AN - SCOPUS:85139093928
SN - 1742-6405
VL - 19
JO - AIDS Research and Therapy
JF - AIDS Research and Therapy
IS - 1
M1 - 47
ER -